2008 Press ReleasesTo search the press release archives for previous years, please click on the year of interest above before entering your keywords.
 |
| Date | Title | | | Dec.31.08 | Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum| CORONA, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals,
today announced that its subsidiary, Watson Laboratories, Inc., has received
approval from the United States Food and Drug Administration to market its
over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg
and 4 mg strengths.
Nicotine Polacrilex Gum, coated mint flavor, is the generic equivalent of
GlaxoSmith... |
|  | | Dec.29.08 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)| CORONA, CA — December 29, 2008 — Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets, 0.15 mg/0.02 mg and 0.01 mg and placebo tablets (28- day regimen). Desogestrel/ethinyl estradiol and ethinyl... |
| | | Dec.16.08 | Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules| CORONA, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its subsidiary, Watson Laboratories, Inc., has received approval today
from the United States Food and Drug Administration on its Abbreviated New
Drug Application (ANDA) for galantamine hydrobromide extended-release
capsules, eq. to 8 mg, 16 mg and 24 mg (galantamine base). Galantamine
hydrobromide extended-release capsules are th... |
| | | Nov.26.08 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg| CORONA, Calif., Nov. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its subsidiary, Watson Laboratories, Inc., has received final approval
today from the United States Food and Drug Administration on its Abbreviated
New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release
Tablets (XL) in the 150 mg strength. Bupropion Hydrochloride Extended-Release
Tablets is the generic equivalent... |
| | | Nov.25.08 | Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr| CORONA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
a definitive agreement to acquire a portfolio of generic pharmaceutical
products that are being divested as a result of the proposed merger between
Teva Pharmaceutical Industries, Ltd. and Barr Pharmaceuticals, Inc. The
closing of the product acquisition is contingent upon the consummation of
Teva's merger with Barr.
The portfolio... |
| | | Nov.13.08 | Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer| CORONA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R)
(triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist,
has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Watson is seeking marketing approval of this TRELSTAR(R) formulation for the
palliative treatment of adva... |
| | | Nov.06.08 | Watson to Present at the 2008 Annual Credit Suisse Health Care Conference| CORONA, CA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the 2008 Annual Credit Suisse
Health Care Conference on Wednesday, November 12, 2008 at 8:00 a.m.
Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pha... |
| | | Oct.29.08 | Watson Pharmaceuticals Reports Third Quarter 2008 Results| Total Net Revenue of $641 Million; GAAP EPS $0.62; Adjusted EPS $0.47
CORONA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its third quarter ended September 30, 2008.
Third Quarter 2008 Results
Net revenue for the third quarter 2008 increased $46.0 million or
8 percent from the third quarter 2007 to $640.7 million, and net income was
$71.1 million, or $0.... |
| | | Oct.24.08 | Watson Files Lawsuit Against Barr for OXYTROL Patent Infringement| CORONA, CA, Oct 24, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced that its subsidiary Watson
Laboratories, Inc. has filed a lawsuit in the U.S. District Court of
Delaware against Barr Pharmaceuticals, Inc. and its subsidiary Barr
Laboratories, Inc. for infringement of patents listed in the Orange
Book for Watson's product OXYTROL(R) (Oxybutynin Transdermal System).
The lawsuit is based upo... |
| | | Oct.17.08 | Watson to Host Third Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Oct 17, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its third quarter 2008 financial results on Wednesday,
October 29, 2008 prior to the open of the U.S. financial markets.
The Company will also host a conference call and webcast at 8:30 a.m.
Eastern Daylight Time on October 29, 2008 to discuss its financial
results and provide an update o... |
| | | Oct.08.08 | Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference| - New Research shows that oxybutynin topical gel may be a convenient alternative to currently available treatments for OAB -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented clinical pharmacokinetic data on oxybutynin
chloride topical gel (OTG), its investigational therapy for overactive bladder
(OAB).
Previously, the efficacy and safety of OTG were dem... |
| | | Oct.08.08 | Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)| - RAPAFLO launch anticipated in early 2009 -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM)
(silodosin), the company's new alpha blocker for the treatment of the signs
and symptoms of BPH.
BPH is the number one reason patients visit urologists and is
characterized by urination problems, including decreased... |
| | | Oct.01.08 | Watson Notified of OXYTROL(R) Patent Challenge| CORONA, Calif., Oct 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
the receipt of a Paragraph IV Certification Notice Letter relating to an
Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug
Administration (FDA) by a generic filer requesting approval to market and sell
a generic version of OYXTROL(R) (Oxybutynin Transdermal System). In its Notice
Letter... |
| | | Sep.29.08 | Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences| - Results demonstrate the efficacy, safety and tolerability of RAPAFLO(TM) alone or in combination with treatments for erectile dysfunction -
CORONA, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented efficacy and safety data on silodosin, its
investigational treatment for benign prostatic hyperplasia (BPH, or prostate
enlargement), at two regional meetings of the A... |
| | | Sep.05.08 | Watson Announces Change to Presentation Time at the Morgan Stanley Global Healthcare Unplugged Conference| CORONA, CA, Sep 05, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced a change to its presentation
time at the Morgan Stanley Global Healthcare Unplugged Conference
that is being held on Tuesday, September 9, 2008. Paul Bisaro,
Watson's president and chief executive officer, will provide an
overview and update of the Company's business at 8:00 a.m. Eastern
Daylight Time.
This presentation wil... |
| | | Sep.03.08 | Watson to Present at the Morgan Stanley Global Healthcare Unplugged Conference| CORONA, CA, Sep 03, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Morgan Stanley Global
Healthcare Unplugged Conference on Tuesday, September 9, 2008 at 4:30
p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
P... |
| | | Aug.13.08 | Watson Announces District Court Ruling in Naproxen Sodium Patent Suit| CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the United States District Court for the Southern District of Florida
ruled today that Watson's Naproxen Sodium ER tablets, the generic version of
Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent").
The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially
brought by Elan in October 199... |
| | | Aug.08.08 | Watson Announces Limited Recall Of Fentanyl |
CORONA, CA - August 8, 2008 - Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that one lot of 75 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies. The recalled patches are from Lot Number 92461850, have expiration dates of August 31, 2009 and were manufactured by Watson Laboratories, Inc. The affected lot of Fentanyl Transdermal System patches was shipped to customers b... |
| | | Aug.06.08 | Watson Pharmaceuticals Reports Second Quarter 2008 Results| Total Net Revenue of $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48
CORONA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its second quarter ended June 30, 2008.
Second Quarter 2008 Results
Net revenue for the second quarter 2008 was $622.6 million and net income
was $60.3 million, or $0.53 per diluted share. Net income for the second
quarter 2008 includ... |
| | | Aug.05.08 | Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes| - QTc profile particularly important among BPH patients with cardiovascular
risk factors -
CORONA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- A paper published in the
current issue of Reviews in Urology (2008; 10(2):85-91) concludes that
urologists and other physicians treating benign prostatic hyperplasia (BPH)
should prescribe medications that do not affect the heart's electrical
activity (heart repolarization), especially since most men with BPH are ol... |
| | | Jul.28.08 | Watson Names Clare Carmichael Senior VP Human Resources| CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Clare Carmichael as Senior Vice President, Human Resources.
Ms. Carmichael's appointment follows the planned retirement of long-time
industry professional, Susan Skara, Senior Vice President, Human Resources.
Ms. Carmichael brings to Watson more than 25 years of human resources
experience within the pharmaceutical... |
| | | Jul.28.08 | Mylan Acquires Remaining Interest in Somerset Joint Venture From Watson| PITTSBURGH and CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Mylan
Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today
that Mylan has acquired Watson's 50 percent interest in the Somerset
Pharmaceuticals, Inc. (Somerset) joint venture. Details of the transaction
remain confidential.
Somerset, a proprietary research and development company located in Tampa,
Florida, was formed in 1986, and since 1988, has been owned jointly by both
Mylan and Watson. ... |
| | | Jul.25.08 | Watson Launches Omeprazole Delayed-Release Capsules, 40MG| - 180-Days of Marketing Exclusivity Begins -
CORONA, Calif., July 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that its subsidiary has commenced commercial shipment of its Omeprazole
Delayed-Release Capsules USP product in the 40mg strength from its Davie,
Florida manufacturing facility. In conjunction with the launch, Watson has
180 days of marketing exclusivity for being the first ... |
| | | Jul.21.08 | Watson to Host Second Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Jul 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its second quarter 2008 financial results on Wednesday,
August 6, 2008 prior to the open of the U.S. financial markets. The
Company will also host a conference call and webcast at 8:30 a.m.
Eastern Daylight Time (EDT) on August 6, 2008 to discuss its financial
results and provide an updat... |
| | | Jun.30.08 | Watson Launches Generic MARINOL(R) Capsules| CORONA, Calif., June 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has
launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg
once daily dosage strengths. Dronabinol is the generic version of Solvay
Pharmaceuticals' MARINOL(R) (dronabinol) CIII Capsules, indicated to treat
nausea and vomiting associated wit... |
| | | Jun.05.08 | Watson to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference| CORONA, CA, Jun 05, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Goldman Sachs Twenty-Ninth
Annual Global Healthcare Conference on Wednesday, June 11, 2008 at
8:00 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Wa... |
| | | Jun.03.08 | Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules| CORONA, Calif., June 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received approval from the U.S. Food and Drug Administration
("FDA") of its Abbreviated New Drug Application (ANDA) for Potassium-Chloride
Extended-Release Capsules USP in the 8mEq and 10mEq strengths.
Potassium-Chloride is the generic equivalent to KV Pharmaceutical's
Micro-K(R) Extencaps(R) USP and is indicated for the ... |
| | | Jun.02.08 | Watson Receives Final Approval of Omeprazole Delayed-Release Capsules| CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the U.S. Food and Drug Administration
("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole
Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.
Watson has been awarded 180 days of marketing exclusivity for being the
first to file an ANDA containing a paragraph IV... |
| | | May.28.08 | Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder| CORONA, Calif., May 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that its New Drug Application (NDA) for oxybutynin chloride topical gel (OTG),
has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Watson is seeking marketing approval of this novel transdermal gel of
oxybutynin hydrochloride for the treatment of overactive bladder (OAB).
OTG is a clear,... |
| | | May.23.08 | Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference| CORONA, Calif., May 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the UBS Global Specialty
and Generic Pharmaceuticals Conference on Wednesday, May 28, 2008 at 2:30 p.m.
London BST (9:30 a.m. EDT).
This presentation will be webcast live and can be ... |
| | | May.21.08 | Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder|
- Innovative pipeline products highlight Watson's commitment to urology -
Embargoed Until 2:10 PM EDT
ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented clinical data on two Phase 3 products at the
American Urological Association's annual meeting. The abstracts include a
cardiac safety trial involving silodosin, an in... |
| | | May.13.08 | Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting| - Company to Highlight Significant and Expanding Commitment to the Treatment
of Urological Diseases -
CORONA, Calif., May 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that management will host and webcast a meeting for the investment community
at the American Urological Association (AUA) Annual Meeting taking place in
Orlando, Florida May 17-22, 2008.
The company will ... |
| | | May.12.08 | Watson Pharmaceuticals Announces Appointment of Andrew L. Turner as Chairman of the Board of Directors| - Allen Chao, Ph.D., to Resign from the Board of Directors -
CORONA, Calif., May 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that following the Company's Annual
Stockholder meeting, Allen Chao, Ph.D., Founder and Chairman of the Board,
informed the Company of his decision to resign, effective May 12, 2008, from
his position as a member of the Board of Directors, in order to pursue other
business activities. Dr. Chao was a co-founder o... |
| | | May.09.08 | Watson to Present at the Bank of America 2008 Healthcare Conference| CORONA, Calif., May 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the Bank of America 2008
Healthcare Conference on Wednesday, May 14, 2008 at 12:40 p.m. Pacific
Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investo... |
| | | May.06.08 | Watson Pharmaceuticals to Webcast Its 2008 Annual Meeting of Stockholders| CORONA, Calif., May 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2008 Annual Meeting of
Stockholders on Friday, May 9, 2008 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watson.com. An archived version of the
webcast will be available for 30 days begin... |
| | | May.01.08 | Watson Pharmaceuticals Reports First Quarter 2008 Results| Total Net Revenue of $627 Million; GAAP EPS $0.45; Adjusted EPS $0.55
CORONA, Calif., May 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its first quarter ended March 31, 2008.
First Quarter 2008 Results
Net revenue for the first quarter 2008 was $626.9 million and net income
was $50.6 million, or $0.45 per diluted share. Net income for the first
quarter 2008 included c... |
| | | Apr.30.08 | FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA| - New system addresses the needs of the medical community; builds on proven
efficacy and safety of TRELSTAR(R) -
CORONA, Calif., April 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration has approved MIXJECT(TM), the new
delivery system for TRELSTAR(R) (triptorelin pamoate for injectable
suspension), a palliative treatment for advanced prostate... |
| | | Apr.29.08 | Watson Announces Removal of FDA Official Action Indicated Status at Its Davie, Florida Facility| - Company Announces Completion of FDA Inspection -
CORONA, Calif., April 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration ("FDA") has completed the
inspection of the company's Florida manufacturing facilities and has informed
the Company that it has removed the Official Action Indicated ("OAI") status
at Watson's Davie, Florida site. As a result of... |
| | | Apr.24.08 | Watson Files FDA Application for Generic FENTORA(R)| CORONA, Calif., April 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that its subsidiary Watson Laboratories, Inc. (a Nevada Corporation) has filed
an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market its Fentanyl Buccal Tablets
C-II product prior to the expiration of patents owned by Cephalon, Inc.
Watson's Fentanyl Buccal Tablets C-II p... |
| | | Apr.21.08 | Watson Files FDA Application for Generic YASMIN(R)| Paragraph IV Patent Challenge UnderwayCORONA, CA, Apr 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today confirmed that it has filed an
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market its Drospirenone and
Ethinyl Estradiol tablets (3.00 mg/0.03 mg) combination oral
contraceptive product prior to the expiration of patents owned by
Bay... |
| | | Apr.21.08 | Watson to Host First Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Apr 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its first quarter 2008 financial results on Thursday, May 1,
2008 prior to the open of the U.S. financial markets. The Company
will also host a conference call and webcast at 8:30 a.m. Eastern
Daylight Time (EDT) on May 1, 2008 to discuss its financial results
and provide an update on the... |
| | | Mar.13.08 | Watson Files FDA Application for Generic LYBREL(R)| - Paragraph IV Patent Challenge Underway -
CORONA, Calif., March 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market its
Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg)
extended-cycle oral contraceptive product prior to the expiration o... |
| | | Mar.12.08 | Watson to Present at Two Upcoming Healthcare Conferences| Cowen's 28th Annual Healthcare Conference on March 17, 2008; Lehman Brothers' 11th Annual Global Healthcare Conference on March 19, 2008CORONA, CA, Mar 12, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the company will provide
an overview and update of the Company's business at two upcoming
healthcare conferences:
-- Paul Bisaro, Watson's President and Chief Executive Officer, wil... |
| | | Mar.04.08 | Watson Files Application for Generic SEASONIQUE(R)| CORONA, Calif., March 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market its
levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral
contraceptive product, prior to the expiration of patents owned by Duramed
Pharmaceuticals, Inc.... |
| | | Feb.20.08 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook|
Fourth Quarter 2007:
Total Net Revenue of $627 Million;
GAAP EPS $0.34; Adjusted EPS $0.35
Fiscal Year 2007:
Total Net Revenue Reaches $2.50 Billion;
2007 GAAP EPS $1.27; 2007 Adjusted EPS $1.37
CORONA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company,... |
| | | Feb.13.08 | Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities| CORONA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration ("FDA") has initiated an inspection
of the company's Florida facilities. No information regarding the duration or
outcome of the inspection is known.
Since September 2005, the Davie, Florida manufacturing facility has been
under Official Action Indicated ("OAI"). During that time, Watson h... |
| | | Feb.12.08 | Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia| CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its New Drug Application (NDA) for silodosin, a novel alpha(1)-
adrenoreceptor antagonist, has been accepted for filing by the U.S. Food and
Drug Administration (FDA). Watson is seeking marketing approval of silodosin
from the FDA for the treatment of the signs and symptoms associated with
benign prostatic hyperplasia (BPH), or en... |
| | | Feb.07.08 | Watson Names Francois Menard Senior VP Generics Research and Development| CORONA, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Francois A. Menard, Ph.D., 48, as Senior Vice President,
Generics Research and Development.
Dr. Menard brings to Watson more than 20 years of pharmaceutical research
and development experience, specifically in the areas of pharmaceutical and
analytical development, biopharmaceutics, project management and regulator... |
| | | Feb.05.08 | Watson to Distribute Alendronate Tablets| CORONA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the company expects to initiate shipments of alendronate sodium in the 35
and 70 mg once weekly dosage strengths when Fosamax(R) loses market
exclusivity, which is anticipated to occur at the close of business on
February 6, 2008. Alendronate sodium is the generic version of Merck's
Fosamax(R) tablets, indicated for the treatment o... |
| | | Feb.01.08 | Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| CORONA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the 2008 Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday,
February 5, 2008 at 1:40 p.m. Eastern Standard Time.
This presentation will be webcast live and can be... |
| | | Jan.24.08 | Watson to Host Fourth Quarter and Full Year 2007 Earnings Conference Call and Webcast| CORONA, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its fourth quarter and full year 2007
financial results on Wednesday, February 20, 2008 prior to the open of the
U.S. financial markets. The Company will also host a conference call and
webcast at 8:30 a.m. Eastern Standard Time (EST) on February 20, 2008 to
discuss its financial results and provide ... |
| | | Jan.07.08 | Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder| - Company on Target to File NDA in Second Quarter of 2008 -
CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced
positive results today from its Phase 3 study of oxybutynin topical gel (OTG)
in patients with overactive bladder (OAB). The study met its primary endpoint
of a statistically significant reduction in incontinence episodes, and
secondary endpoints of reduction in frequency an... |
| | | Jan.03.08 | Watson Launches Generic Biaxin(R) XL| CORONA, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg
strength. Watson's Clarithromycin Extended-Release product is the generic
equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent
infections that are proven or strongly suspected to be caused by susceptible
bacteria. For the 12-months ending ... |
| | | Jan.02.08 | Watson Receives FDA Approval for Generic DuoNeb(R)| CORONA, Calif., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
Ipratropium Bromide and Albuterol Sulfate Inhalation Solution in the
0.5 mg/3 mg strength.
Watson's Ipratropium Bromide and Albuterol Sulfate product is the gene... |
| |
|
|
|
